Association between the triple-negative breast cancer and the risk of BRCA1 mutation: a Meta-analysis

Abstract

Abstract:Objective To systematically evaluate the risk of BRCA1 mutation in patients with triplenegative breast cancer (TNBC). MethodsArticles about the association between the TNBC and BRCA1 mutation were retrieved from database, such as PubMed, CNKI, Wanfang, VIP and CBM databases. The odds ratio (OR) was used to evaluate the risk of BRCA1 mutation in TNBC compared with nonTNBC. Rev Man 5.2 software was applied to perform the Metaanalysis. ResultsA total of 23 articles were eligible for the Metaanalysis, including 1 104 patients with TNBC and 4 245 patients with non-TNBC. The pooled OR was 7.67 and 95%CI(6.24, 9.42), and the difference was statistically significant (Z=19.38, P<0.000 01). In the subgroup analysis about the race, the pooled OR for Asian was 6.67 and 95%CI (4.98, 8.95). The pooled OR for Caucasian was 8.83 and 95%CI (6.61, 11.80). There was statistically significant difference in the pooled OR between the Asian and the Caucasian（Z=14.74,P＜0.000 01）. ConclusionThe patients with TNBC are 7.67 times more likely to have BRCA1 mutation compared with nonTNBC phenotype. Largesample randomized controlled trials are warranted to demonstrate the detection of BRCA1 mutation can be a conventional application in clinical for the patients with TNBC.

Key words:Breast neoplasms,Genes, BRCA1,Meta-analysis

Zhang Li, Long Xinghua. Association between the triple-negative breast cancer and the risk of BRCA1 mutation: a Meta-analysis[J]. Journal of International Oncology, 2015, 42(1): 32-36.

References

［1］ Zhang J, Wang Y, Yin Q, et al. An associated classification of triple negative breast cancer: the risk of relapse and the response to chemotherapy［J］. Int J Clin Exp Pathol, 2013, 6(7): 1380-1391. ［2］ Wang L, Di LJ. BRCA1 and estrogen/estrogen receptors in breast cancer: where they interact?［J］. Int J Biol Sci, 2014, 10(5): 566-575. ［3］ Corkery B, Crown J, Clynes M, et al. Epidermal growth factor receptor as a potential therapeutic target in triplenegative breast cancer［J］. Ann Oncol, 2009, 20(5): 862-867. ［4］ Atchley DP, Albarracin CT, Lopez A, et al. Clinical and pathologic characteristics of patients with BRCApositive and BRCAnegative breast cancer［J］. J Clin Oncol, 2008, 26(26): 4282-4288. ［5］ Bayraktar S, GutierrezBarrera AM, Lin H, et al. Outcome of metastatic breast cancer in selected women with or without deleterious BRCA mutations［J］. Clin Exp Metastasis, 2013, 30(5): 631-642. ［6］ Byrski T, Gronwald J, Huzarski T, et al. Response to neoadjuvant chemotherapy in women with BRCA1positive breast cancers［J］. Breast Cancer Res Treat, 2008, 108(2): 289-296. ［7］ Chen W, Pan K, Ouyang T, et al. BRCA1 germline mutations and tumor characteristics in Chinese women with familial or earlyonset breast cancer［J］. Breast Cancer Res Treat, 2009, 117(1): 55-60. ［8］ Comen E, Davids M, Kirchhoff T, et al. Relative contributions of BRCA1 and BRCA2 mutations to ′′triplenegative′′ breast cancer in Ashkenazi women［J］. Breast Cancer Res Treat, 2011, 129(1): 185-190. ［9］ Haffty BG, Yang Q, Reiss M, et al. Locoregional relapse and distant metastasis in conservatively managed triple negative earlystage breast cancer［J］. J Clin Oncol, 2006, 24(36): 5652-5657. ［10］ Kwong A, Wong LP, Wong HN, et al. Clinical and pathological characteristics of Chinese patients with BRCA related breast cancer［J］. HUGO J, 2009, 3(1-4): 63-76. ［11］ Lee E, MckeanCowdin R, Ma H, et al. Characteristics of triplenegative breast cancer in patients with a BRCA1 mutation: results from a populationbased study of young women［J］. J Clin Oncol, 2011, 29(33): 4373-4380. ［12］ Li WF, Hu Z, Rao NY, et al. The prevalence of BRCA1 and BRCA2 germline mutations in highrisk breast cancer patients of Chinese Han nationality: two recurrent mutations were identified［J］. Breast Cancer Res Treat, 2008, 110(1): 99-109. ［13］ Musolino A, Bella MA, Bortesi B, et al. BRCA mutations, molecular markers, and clinical variables in earlyonset breast cancer: a populationbased study［J］. Breast, 2007, 16(3): 280-292. ［14］ Noh JM, Han BK, Choi DH, et al. Association between BRCA mutation status, pathological findings, and magnetic resonance imaging features in patients with breast cancer at risk for the mutation［J］. J Breast Cancer, 2013, 16(3): 308-314. ［15］ Ou J, Wu T, Sijmons R, et al. Prevalence of BRCA1 and BRCA2 germline mutations in breast cancer women of multiple ethnic region in northwest China［J］. J Breast Cancer, 2013, 16(1): 50-54. ［16］ Phuah SY, Looi LM, Hassan N, et al. Triplenegative breast cancer and PTEN (phosphatase and tensin homologue) loss are predictors of BRCA1 germline mutations in women with earlyonset and familial breast cancer, but not in women with isolated lateonset breast cancer［J］. Breast Cancer Research, 2012, 14(6): R142-150. ［17］ Pristauz G, Petru E, Stacher E, et al. Androgen receptor expression in breast cancer patients tested for BRCA1 and BRCA2 mutations［J］. Histopathology, 2010, 57(6): 877-884. ［18］ Rakha EA, Elsheikh SE, Aleskandarany MA, et al. Triplenegative breast cancer: distinguishing between basal and nonbasal subtypes［J］. Clin Cancer Res, 2009, 15(7): 2302-2310. ［19］ Xu J, Wang B, Zhang Y, et al. Clinical implications for BRCA gene mutation in breast cancer［J］. Mol Biol Rep, 2012, 39(3): 3097-3102. ［20］ Yip CH, Taib NA, Choo WY, et al. Clinical and pathologic differences between BRCA1, BRCA2, and nonBRCAassociated breast cancers in a multiracial developing country［J］. World J Surg, 2009, 33(10): 2077-2081. ［21］ Zhang J, Pei R, Pang Z, et al. Prevalence and characterization of BRCA1 and BRCA2 germline mutations in Chinese women with familial breast cancer［J］. Breast Cancer Res Treat, 2012, 132(2): 421-428. ［22］刘军杰, 陈圆圆, 李智贤, 等. 广西地区散发性乳腺癌BRCA1突变及其相关临床、组织病理特征的研究［J］. 广西医科大学学报, 2013, 30(4): 496-499. ［23］李文凤. 中国家族性/早发性乳腺癌人群中BRCA1和BRCA2基因突变的研究［D］. 上海:复旦大学, 2007. ［24］杨云振. 宁夏地区回、汉族乳腺癌BRCA1基因突变分析［D］. 银川:宁夏医科大学, 2010. ［25］欧江华, 吴涛, 倪多, 等. 68例中国新疆多民族地区遗传性乳腺癌患者BRCA1和BRCA2突变研究［J］. 中国肿瘤临床, 2012, 29(20): 1539-1541. ［26］王景, 陈耀平, 康毓芝, 等. 宁夏回族乳腺癌BRCA1基因突变与ER、PR、CerbB2表达的关系［J］. 宁夏医科大学学报, 2011, 33(12): 1135-1137. ［27］刘静, 张娟, 欧阳涛, 等. 中国汉族BRCA1/2突变的乳腺癌家系中其他肿瘤发病风险分析［J］. 国际肿瘤学杂志, 2013, 40(5): 389-392.

[1]	Wang Ying, Liu Nan, Guo Bing.Advances of antibody-drug conjugate in the therapy of metastatic breast cancer[J]. Journal of International Oncology, 2024, 51(6): 364-369.
[2]	Sa Qiang, Xu Hangcheng, Wang Jiayu.Advances in immunotherapy for breast cancer[J]. Journal of International Oncology, 2024, 51(4): 227-234.
[3]	Yang Zhi, Lu Yiqiao, Gu Huayan, Ding Jialing, Guo Guilong.Research progress of tumor microenvironment mediated drug resistance in targeted therapy of breast cancer[J]. Journal of International Oncology, 2024, 51(4): 235-238.
[4]	Chen Boguang, Wang Sugui, Zhang Yongjie.Role of serum cholinesterase and inflammatory markers in the prognosis of stage ⅠA -ⅢA breast cancer[J]. Journal of International Oncology, 2024, 51(2): 73-82.
[5]	Gu Huayan, Zhu Teng, Guo Guilong.Breast microbiota and breast cancer： present and future[J]. Journal of International Oncology, 2024, 51(1): 55-58.
[6]	Wang Jing, Xu Wenting.Value of NLR， CEA combined with coagulation indicators in the differential diagnosis of benign and malignant breast nodules with a diameter ≤ 1.0 cm[J]. Journal of International Oncology, 2023, 50(9): 520-526.
[7]	Feng Chengtian, Huang Furong, Cao Shiyu, Wang Jianyu, Nanding Abiyasi, Jiang Yongdong, Zhu Juanying.Relationships between HER2 protein expression and imaging features in HER2 positive breast cancer patients[J]. Journal of International Oncology, 2023, 50(9): 527-531.
[8]	Feng Dongxu, Wu Wei, Gao Pingfa, Wang Jun, Shi Lijuan, Chen Dawei, Li Wenbing, Zhang Meifeng.Effects of miR-451 on glycolysis and apoptosis of breast cancer cells by regulating Rho/ROCK1 pathway[J]. Journal of International Oncology, 2023, 50(8): 449-456.
[9]	Pan Shulan, Liu Chang, He Ping.Effect of fritinib on angiogenesis, tumor growth and IRE1-ASK1-JNK pathway in triple negative breast cancer[J]. Journal of International Oncology, 2023, 50(8): 457-462.
[10]	Wang Wende, Zeng De.Research progress on the mechanism of endocrine therapy resistance for breast cancer[J]. Journal of International Oncology, 2023, 50(6): 352-356.
[11]	Li Qingshan, Xie Xin, Zhang Nan, Liu Shuai.Research progress on the application of combining radiotherapy and systemic therapy in breast cancer[J]. Journal of International Oncology, 2023, 50(6): 362-367.
[12]	Zhu Jun, Huang Meijin, Li Yuan, Liu Zegang, Xun Xin, Chen Hong.Research progress on targeted therapy of breast cancer with low expression of HER2[J]. Journal of International Oncology, 2023, 50(4): 236-240.
[13]	Zhou Ting, Xu Shaohua, Mei Lin.Efficacy and safety of bevacizumab combined with capecitabine in the treatment of advanced breast cancer[J]. Journal of International Oncology, 2023, 50(3): 144-149.
[14]	Li Lixi, Zhang Di, Luo Yang, Ma Fei.Clinical application of PARP inhibitors in breast cancer[J]. Journal of International Oncology, 2023, 50(2): 91-96.
[15]	Geng Rui, Ma Junqiang, Guo Qiang, Niu Zhaofeng.Tendency of elderly patients with breast cancer to choose comprehensive treatment mode and its influencing factors[J]. Journal of International Oncology, 2023, 50(11): 650-654.